Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

JF Gainor, G Curigliano, DW Kim, DH Lee… - The lancet …, 2021 - thelancet.com
Background Oncogenic alterations in RET have been identified in multiple tumour types,
including 1–2% of non-small-cell lung cancers (NSCLCs). We aimed to assess the safety …
被引用次数：333 相关文章

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

JF Gainor, G Curigliano, DW Kim… - The Lancet …, 2021 - mayoclinic.elsevierpure.com
Background: Oncogenic alterations in RET have been identified in multiple tumour types,
including 1–2% of non-small-cell lung cancers (NSCLCs). We aimed to assess the safety …

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.

JF Gainor, G Curigliano, DW Kim… - The lancet …, 2021 - digitalcommons.providence.org
BACKGROUND: Oncogenic alterations in RET have been identified in multiple tumour
types, including 1-2% of non-small-cell lung cancers (NSCLCs). We aimed to assess the …

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

이대호 - 2021 - oak.ulsan.ac.kr
Background Oncogenic alterations in RET have been identified in multiple tumour types,
including 1-2% of non-small-cell lung cancers (NSCLCs). We aimed to assess the safety …

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

JF Gainor, G Curigliano, D Kim, DH Lee… - THE LANCET …, 2021 - air.unimi.it
Background: Oncogenic alterations in RET have been identified in multiple tumour types,
including 1-2% of non-small-cell lung cancers (NSCLCs). We aimed to assess the safety …

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

JF Gainor, G Curigliano, DW Kim… - The Lancet …, 2021 - providence.elsevierpure.com
Background: Oncogenic alterations in RET have been identified in multiple tumour types,
including 1–2% of non-small-cell lung cancers (NSCLCs). We aimed to assess the safety …

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

JF Gainor, G Curigliano, DW Kim… - The Lancet …, 2021 - yonsei.elsevierpure.com
Background: Oncogenic alterations in RET have been identified in multiple tumour types,
including 1–2% of non-small-cell lung cancers (NSCLCs). We aimed to assess the safety …

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

JF Gainor, G Curigliano, DW Kim… - The Lancet …, 2021 - snucm.elsevierpure.com
Background: Oncogenic alterations in RET have been identified in multiple tumour types,
including 1–2% of non-small-cell lung cancers (NSCLCs). We aimed to assess the safety …

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

JF Gainor, G Curigliano, DW Kim… - The lancet …, 2021 - mdanderson.elsevierpure.com
Background: Oncogenic alterations in RET have been identified in multiple tumour types,
including 1–2% of non-small-cell lung cancers (NSCLCs). We aimed to assess the safety …

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

JF Gainor, G Curigliano, DW Kim, DH Lee… - The Lancet …, 2021 - s-space.snu.ac.kr
Background Oncogenic alterations in RET have been identified in multiple tumour types,
including 1 & ndash; 2% of non-small-cell lung cancers (NSCLCs). We aimed to assess the …